Trisalus Life Sciences, Inc. cash flow statement
In fiscal 2025, Trisalus Life Sciences, Inc.'s operations generated −$18.0m of cash; it spent $918,000 on capital projects, leaving free cash flow of −$18.9m.
Cash flow statement
| Fiscal year | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|
| Cash from operations | −32 | −51 | −41 | −18 | −23 |
| Depreciation and amortisation | 0 | 1 | 1 | 1 | 1 |
| Stock-based pay | 0 | 1 | 5 | 9 | 11 |
| Capital spending | 1 | 1 | 0 | 1 | 0 |
| Free cash flow | −33 | −51 | −41 | −19 | −23 |
| Free cash flow after stock pay | −33 | −53 | −47 | −28 | −34 |
| Share buybacks | 232 | — | — | — | — |
| Shares issued | — | 0 | 15 | 22 | 44 |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | −11 | −6 | −4 | −7 | −4 | −2 | −6 | −10 |
| Depreciation and amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based pay | 1 | 2 | 2 | 3 | 3 | 2 | 2 | 3 |
| Capital spending | 0 | 0 | 1 | −0 | 0 | 0 | 0 | 0 |
| Free cash flow | −11 | −6 | −5 | −7 | −4 | −3 | −7 | −10 |
| Free cash flow after stock pay | −12 | −7 | −7 | −10 | −7 | −5 | −9 | −13 |
| Shares issued | 6 | 3 | 0 | 20 | 2 | −0 | 43 | 0 |
Compare with peers
- Koru Medical Systems, Inc. cash flow
- Clearpoint Neuro, Inc. cash flow
- Sanuwave Health, Inc. cash flow
- Myomo, Inc. cash flow
- Senseonics Holdings, Inc. cash flow
Head to head: KRMD vs TLSICLPT vs TLSISNWV vs TLSIMYO vs TLSI
More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies